Abstract：
Cerebral ischemia-reperfusion injury (CIRI) poses significant challenges for drug development due to its complex pathogenesis. Astrocyte involvement in CIRI pathogenesis has led to the development of novel astrocyte-targeting drug strategies. To comprehensively review the current literature, we conducted a thorough analysis from January 2012 to December 2023, identifying 82 drugs aimed at preventing and treating CIRI. These drugs target astrocytes to exert potential benefits in CIRI, and their primary actions include modulation of relevant signaling pathways to inhibit neuroinflammation and oxidative stress, reduce cerebral edema, restore blood-brain barrier integrity, suppress excitotoxicity, and regulate autophagy. Notably, active components from traditional Chinese medicines (TCM) such as Salvia miltiorrhiza, Ginkgo, and Ginseng exhibit these important pharmacological properties and show promise in the treatment of CIRI. This review highlights the potential of astrocyte-targeted drugs to ameliorate CIRI and categorizes them based on their mechanisms of action, underscoring their therapeutic potential in targeting astrocytes.
摘要：
脑缺血再灌注损伤(CIRI)由于其复杂的发病机制,对药物开发提出了重大挑战。星形胶质细胞参与CIRI发病机制导致了新型星形胶质细胞靶向药物策略的发展。为了全面回顾当前的文献，我们从2012年1月至2023年12月进行了全面分析,确定了82种旨在预防和治疗CIRI的药物.这些药物靶向星形胶质细胞在CIRI中发挥潜在的益处，它们的主要作用包括调节相关信号通路以抑制神经炎症和氧化应激，减少脑水肿，恢复血脑屏障的完整性，抑制兴奋毒性，并调节自噬。值得注意的是,丹参等中药活性成分，银杏,和人参表现出这些重要的药理特性，并在CIRI的治疗中显示出希望。这篇综述强调了星形胶质细胞靶向药物改善CIRI的潜力，并根据其作用机制对其进行了分类。强调了它们在靶向星形胶质细胞方面的治疗潜力。
